RER1 Stock Overview
Engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Recordati Industria Chimica e Farmaceutica S.p.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €50.90 |
| 52 Week High | €54.65 |
| 52 Week Low | €44.01 |
| Beta | 0.40 |
| 11 Month Change | -4.32% |
| 3 Month Change | -2.96% |
| 1 Year Change | 15.03% |
| 33 Year Change | -4.82% |
| 5 Year Change | 41.15% |
| Change since IPO | 76.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| RER1 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -1.1% | 1.2% | 1.3% |
| 1Y | 15.0% | -19.7% | 7.9% |
Return vs Industry: RER1 exceeded the German Pharmaceuticals industry which returned -19.7% over the past year.
Return vs Market: RER1 exceeded the German Market which returned 7.9% over the past year.
Price Volatility
| RER1 volatility | |
|---|---|
| RER1 Average Weekly Movement | 2.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RER1 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RER1's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1926 | 4,455 | Rob Koremans | www.recordati.com |
Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceuticals in Italy and internationally. It operates through Specialty and Primary Care and Rare Diseases segments. The company’s product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS for the treatment of cystine crystal deposits in the cornea.
Recordati Industria Chimica e Farmaceutica S.p.A. Fundamentals Summary
| RER1 fundamental statistics | |
|---|---|
| Market cap | €10.54b |
| Earnings (TTM) | €423.12m |
| Revenue (TTM) | €2.27b |
24.9x
P/E Ratio4.6x
P/S RatioIs RER1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RER1 income statement (TTM) | |
|---|---|
| Revenue | €2.27b |
| Cost of Revenue | €666.44m |
| Gross Profit | €1.60b |
| Other Expenses | €1.18b |
| Earnings | €423.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.07 |
| Gross Margin | 70.63% |
| Net Profit Margin | 18.65% |
| Debt/Equity Ratio | 81.6% |
How did RER1 perform over the long term?
See historical performance and comparison